An overview of the rare parotid gland cancer

Kimberley Ho, Helen Lin, David K. Ann, Peiguo G. Chu, Yun Yen

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

Original languageEnglish
Article number40
JournalHead and Neck Oncology
Volume3
Issue number1
DOIs
Publication statusPublished - Sep 21 2011
Externally publishedYes

Fingerprint

Parotid Neoplasms
Parotid Gland
Radiotherapy
Salivary Gland Neoplasms
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Carcinogenesis
Epidemiology
Clinical Trials
Pathology
Neoplasm Metastasis
Drug Therapy
Therapeutics

Keywords

  • endosomal sorting complexes required for transport
  • epidermal growth factor receptor
  • multi-vesicular bodies
  • Parotid gland cancer
  • salivary gland cancer
  • targeted therapeutics
  • vacuolar protein sorting-associated protein 4B
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology

Cite this

An overview of the rare parotid gland cancer. / Ho, Kimberley; Lin, Helen; Ann, David K.; Chu, Peiguo G.; Yen, Yun.

In: Head and Neck Oncology, Vol. 3, No. 1, 40, 21.09.2011.

Research output: Contribution to journalReview article

Ho, Kimberley ; Lin, Helen ; Ann, David K. ; Chu, Peiguo G. ; Yen, Yun. / An overview of the rare parotid gland cancer. In: Head and Neck Oncology. 2011 ; Vol. 3, No. 1.
@article{5f62692943cb40f88ab1481c77532001,
title = "An overview of the rare parotid gland cancer",
abstract = "Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.",
keywords = "endosomal sorting complexes required for transport, epidermal growth factor receptor, multi-vesicular bodies, Parotid gland cancer, salivary gland cancer, targeted therapeutics, vacuolar protein sorting-associated protein 4B, vascular endothelial growth factor",
author = "Kimberley Ho and Helen Lin and Ann, {David K.} and Chu, {Peiguo G.} and Yun Yen",
year = "2011",
month = "9",
day = "21",
doi = "10.1186/1758-3284-3-40",
language = "English",
volume = "3",
journal = "Head and Neck Oncology",
issn = "1758-3284",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - An overview of the rare parotid gland cancer

AU - Ho, Kimberley

AU - Lin, Helen

AU - Ann, David K.

AU - Chu, Peiguo G.

AU - Yen, Yun

PY - 2011/9/21

Y1 - 2011/9/21

N2 - Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

AB - Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

KW - endosomal sorting complexes required for transport

KW - epidermal growth factor receptor

KW - multi-vesicular bodies

KW - Parotid gland cancer

KW - salivary gland cancer

KW - targeted therapeutics

KW - vacuolar protein sorting-associated protein 4B

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=80052869608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052869608&partnerID=8YFLogxK

U2 - 10.1186/1758-3284-3-40

DO - 10.1186/1758-3284-3-40

M3 - Review article

VL - 3

JO - Head and Neck Oncology

JF - Head and Neck Oncology

SN - 1758-3284

IS - 1

M1 - 40

ER -